

TARGET	Secondary care, Preoperative Assessment
AUDIENCE	
PATIENT GROUP	Patients attending preoperative assessment for elective
	surgery.

Clinical Guidelines Summary

- Patients with chronic pain issues or high opioid use should be identified early in the preoperative assessment process.
- Calculators allow for the oral morphine equivalent of medications taken to be calculated and noted to identify opioid overuse and potential tolerance in patients prior to surgery.
- Patients on other regular potent analgesics, neuropathic pain agents and those on ketamine or methadone should also be highlighted and managed appropriately.
- Chronic pain patients with implanted devices should be identified and specialist support sought as necessary.
- Complex patients and those with previous difficult perioperative pain control should also be discussed with anaesthetic and acute pain teams and plans made for pain management in the perioperative period.



Introduction

Chronic pain affects between one third and one half of the UK population. This corresponds to approximately 28 million adults (1). The annual number of surgical procedures in the UK totals between 4-8 million (2) (3). It is common for chronic pain patients to be found in this population. Therefore, the perioperative management of these complex patients must be considered. Early identification of complex patients by surgeons and preoperative assessment staff is highly recommended and can facilitate forward planning (4). This allows time to involve the experience of others (e.g. anaesthetists, pain specialists, psychologists, GP, occupational therapists and physiotherapists etc). Communication and involvement of the patient is a central tenet of successful perioperative management. There is no good evidence to support the prescribing of strong opioids in the management of chronic pain (5). A small number of patients may benefit from a low and intermittent prescription of strong opioid, but the number of chronic patient patients on long-term opioids should theoretically be declining. Nevertheless, patients on long-term opioids still frequently present to preoperative assessment service. The growing importance of the perioperative management of opioids has been emphasised in both an International Consensus Statement published in Anaesthesia and a multidisciplinary guideline endorsed by the Faculty of Pain Medicine (FPM) and the Centre for Perioperative Care (CPOC) (6) (3). A number of recommendations for best practice have been identified.

Preoperative Assessment

This is an opportunity for perioperative planning, which may involve discussion with anaesthetic staff.

Prehabilitation is possible in this group of patients.

This may take the form brief interventions to reduce preoperative anxiety and resultant catastrophising. This should be extended to the management of all patients in the preoperative setting, as there is a known correlation between anxiety and post-operative pain intensity (7). Strategies to accomplish this include providing information on realistic expectations of postoperative pain, assurance that it is a management priority, and that multimodal strategies are used to decrease discomfort.

As per the FPM and the CPOC, it is also an opportunity to identify of opioid overuse and potentially involve specialist services for preoperative weaning in selected cases. SIGN 136 identifies a ceiling dose of 90mg oral morphine equivalent as the upper limit of what should be prescribed (8). Hyperalgesia may also be an issue, and tolerance is likely above 60mg oral morphine equivalent (CPOC) (3).

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026



Areas to pay specific importance to, and potentially seek advice regarding include (4) (3) (6):

• Screening for chronic pain and opioid use. An oral morphine equivalent should be noted. A useful calculator for doing so is available at: https://paindata.org/calculator.php

CPOC recommend that opioid weaning should be considered prior to surgery if feasible. This may require the input of a pain specialist.

- Patients taking regular potent analgesics, antidepressants or antiepileptics who the enteral route will not be available for more than 24 hours.
- All patients taking ketamine or methadone.
- Patients with implanted devices.
- Patients anxious about the postoperative control of their acute surgical and background chronic pain.
- Patients with a history of opioid addiction.
- Previous difficult perioperative pain control.

It is common for this group of patients to be treated with multiple analgesics as part of their ongoing chronic condition. The perioperative management of these medications may present questions for the preoperative assessment service in relation to management of analgesics preoperatively. More uncommonly, they may have an implanted device for which specialist advice should always be sought. Advice regarding both scenarios is listed below

Pre-operative Medication Management

Opioids Examples include: Common PO Opioids

- Oxycodone
- Morphine
- Codeine
- Dihydrocodeine
- Tapentadol
- Tramadol

Patches

- Fentanyl
- Buprenorphine

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026



All opioids, including patches. > Calculate OME. > If > 90mg in 24 hours, seek advice from referring team regarding possible taper. SIGN 136 recommends specialist advice above this dose. > Otherwise, advise to take as usual (4).

Special Instances

- Methadone (mu agonist, NMDA antagonist and MAOi.) > Advise to take as usual (9). > Perioperative Mx. Treat as any opioid tolerant patient. Dependent on if enteral route available. Continue PO if possible, otherwise switch to PCA with background.
- Buprenorphine (partial mu agonist, kappa and delta antagonist. Very slow dissociation.) > Advise to take as usual (9). > Perioperative Mx. Maximise opioid sparing adjuncts/regional techniques. Use regular full agonist opioids. Dose required may be appreciably higher. Consider HDU post operatively. > May be prescribed in combination with naloxone as Suboxone. The naloxone component is used to prevent parenteral diversion, and has no significant clinical effect when taken sublingually or enterally. Therefore advise to take as usual.
- Naltrexone (long acting opioid antagonist [48-72 hours] not typically used in chronic pain. Used in patients who are trying to remain abstinent, but does has important perioperative considerations.) > Advise stopping 72 hours prior to surgery (9). > Perioperative Mx. Post chronic use, cessation is associated with doubling of mu and delta opioid receptors. Returns to baseline in approximately 6 days. May result in extreme opioid sensitivity. Maximise adjuncts/regional techniques.

Neuropathic Agents

Multiple agents are used in the treatment of neuropathic pain. They can be classified broadly as antiepileptics or antidepressants. NICE guidance recommends the use of amitriptyline, duloxetine, gabapentin or pregabalin as initial treatment, so it is likely that these will be the most commonly encountered (10). However, a number of other treatments may also be encountered including lidocaine, sativa, capsaicin, lacosamide, lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, topiramate, venlafaxine and sodium valproate. > Advise to take as usual (4).

Devices

- Spinal Cord Stimulator (single or multiple leads containing electrodes that are placed in the dorsal epidural space) > Contact tertiary service to arrange deactivation, and plan for reactivation post operatively (4) (11).
- Intrathecal Drug Delivery System (intrathecal catheter connected to a drug reservoir usually morphine) > Continue perioperatively and supplement patient with additional analgesia for the acute event enterally and/or parenterally (4) (12).

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026



References/Evidence

- (1) Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ open; BMJ Open 2016;6(6):e010364.
- (2) Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. Br J Anaesth 2017;119(2):249-257.
- (3) Faculty of Pain Medicine. Surgery & Opioids: Best Practice Guidelines 2021. 2021; Available at: https://fpm.ac.uk/sites/fpm/files/documents/2021-03/surgery-and-opioids2021_2.pdf. Accessed April 14th, 2021.
- (4) Farrell C, McConaghy P. Perioperative management of patients taking treatment for chronic pain. BMJ 2012;345:e4148.
- (5) Faculty of Pain Medicine. Opioids Aware. 2020; Available at: https://www.fpm.ac.uk/opioids-aware. Accessed April 14th, 2021.
- (6) Levy N, Quinlan J, El-Boghdadly K, Fawcett WJ, Agarwal V, Bastable RB, et al. An international multidisciplinary consensus statement on the prevention of opioid-related harm in adult surgical patients. Anaesthesia 2021;76(4):520-536.
- (7) Villa G, Chelazzi C, Amass T, Lanini I, De Gaudio AR, Romagnoli S, et al. Effects of psychological interventions on anxiety and pain in patients undergoing major elective abdominal surgery: a systematic review. Perioperative medicine (London) 2020;9(1):1-38.
- (8) Scottish Intercollegiate Guideline Network (SIGN). SIGN 136: Management of Chronic Pain. 2019; Available at: https://www.sign.ac.uk/assets/sign136.pdf. Accessed April 14th, 2021.
- (9) Simpson G, Jackson M. Perioperative management of opioid-tolerant patients. BJA education 2017;17(4):124-128.
- (10) National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist setting. Clinical guideline [CG173]. 2020; Available at: https://www.nice.org.uk/guidance/cg173. Accessed April 12th, 2021.
- (11) Bull C, Baranidharan G. Spinal cord stimulators and implications for anaesthesia. BJA education; BJA Educ 2020;20(6):182-183. (12) Lynch L. Intrathecal drug delivery systems. Continuing education in anaesthesia, critical care & pain 2014;14(1):27-31.

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026



Appendices

1. Governance information for Guidance document

Lead Author(s):	S McConnell
Endorsing Body:	Perioperative Medicine Group
Version Number:	2
Approval date	September 2024
Review Date:	September 2026
Responsible Person (if different from lead author)	

CONSULTATION AND DIS	TRIBUTION RECORD
Contributing Author / Authors	J McGuinness, K Ramage, G Haldane, A Simpson, S McConnell
Consultation Process / Stakeholders:	Perioperative Medicine Group
Distribution	Preoperative assessment departments

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026



CHANGE RE	CHANGE RECORD				
Date	Lead Author	Change	Version No.		
April 2021	J McGuinness	Review of current evidence and guidance on the perioperative management of chronic pain patients.	1		
September 2024	S McConnell	Review and re-draft to updated clinical guidelines format	2		
			3		
			4		
			5		

Lead Author	S McConnell	Date approved	Sept 2024
Version	V.2	Review Date	Sept 2026